Lieven Annemans

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1583682/publications.pdf

Version: 2024-02-01

172457 149698 3,572 106 29 56 citations h-index g-index papers 109 109 109 6072 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	3D-printing techniques in a medical setting: a systematic literature review. BioMedical Engineering OnLine, 2016, 15, 115.	2.7	728
2	The cost of prevention and treatment of pressure ulcers: A systematic review. International Journal of Nursing Studies, 2015, 52, 1754-1774.	5 . 6	313
3	Reducing the costs of chronic kidney disease while delivering quality health care: a call to action. Nature Reviews Nephrology, 2017, 13, 393-409.	9.6	200
4	Effectiveness of respite care in supporting informal caregivers of persons with dementia: a systematic review. International Journal of Geriatric Psychiatry, 2016, 31, 1277-1288.	2.7	130
5	Multicolumn spinal cord stimulation for predominant back pain in failed back surgery syndrome patients: a multicenter randomized controlled trial. Pain, 2019, 160, 1410-1420.	4.2	100
6	Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature. PLoS ONE, 2016, 11, e0146262.	2. 5	94
7	Effectiveness of Supporting Informal Caregivers of People with Dementia: A Systematic Review of Randomized and Non-Randomized Controlled Trials. Journal of Alzheimer's Disease, 2016, 52, 929-965.	2.6	85
8	A school- and community-based intervention to promote healthy lifestyle and prevent type 2 diabetes in vulnerable families across Europe: design and implementation of the Feel4Diabetes-study. Public Health Nutrition, 2018, 21, 3281-3290.	2.2	77
9	Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL). Orphanet Journal of Rare Diseases, 2017, 12, 50.	2.7	72
10	Economic Impact of Integrated Care Models for Patients with Chronic Diseases: A Systematic Review. Value in Health, 2016, 19, 892-902.	0.3	71
11	Current Methodological Issues in the Economic Assessment of Personalized Medicine. Value in Health, 2013, 16, S20-S26.	0.3	70
12	â€~Highest risk–highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. European Heart Journal, 2018, 39, 2546-2550.	2.2	69
13	The cost of pressure ulcer prevention and treatment in hospitals and nursing homes in Flanders: A cost-of-illness study. International Journal of Nursing Studies, 2015, 52, 1166-1179.	5.6	60
14	Impact of palliative home care support on the quality and costs of care at the end of life: a population-level matched cohort study. BMJ Open, 2019, 9, e025180.	1,9	58
15	Total-Body Examination vs Lesion-Directed Skin Cancer Screening. JAMA Dermatology, 2016, 152, 27.	4.1	51
16	Cost Effectiveness of a Novel 10 kHz High-Frequency Spinal Cord Stimulation System in Patients with Failed Back Surgery Syndrome (FBSS). Journal of Long-Term Effects of Medical Implants, 2014, 24, 173-183.	0.7	50
17	HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries. Health Policy, 2019, 123, 140-151.	3.0	43
18	Cost of renal replacement: how to help as many as possible while keeping expenses reasonable?. Nephrology Dialysis Transplantation, 2016, 31, 1251-1261.	0.7	42

#	Article	IF	Citations
19	Fighting the unbearable lightness of neglecting kidney health: the decade of the kidney. CKJ: Clinical Kidney Journal, 2021, 14, 1719-1730.	2.9	41
20	Cost Effectiveness of Varenicline in Belgium, Compared with Bupropion, Nicotine Replacement Therapy, Brief Counselling and Unaided Smoking Cessation. Clinical Drug Investigation, 2009, 29, 655-665.	2.2	40
21	Using linked administrative and disease-specific databases to study end-of-life care on a population level. BMC Palliative Care, 2016, 15, 86.	1.8	40
22	Prevalence and management of antibiotic associated diarrhea in general hospitals. BMC Infectious Diseases, 2015, 15, 129.	2.9	39
23	EQ-5D Versus SF-12 in Coronary Patients: Are They Interchangeable?. Value in Health, 2014, 17, 84-89.	0.3	37
24	Resource Use and Health Care Costs of COPD Patients at the End of Life: A Systematic Review. Journal of Pain and Symptom Management, 2016, 52, 588-599.	1.2	37
25	Predictors of allâ€cause mortality and ischemic events within and beyond 1 year after an acute coronary syndrome: Results from the EPICOR registry. Clinical Cardiology, 2019, 42, 111-119.	1.8	37
26	Cost effectiveness of long-acting risperidone: What can pharmacoeconomic models teach us?. Pharmacoeconomics, 2005, 23, 1-2.	3.3	34
27	Long-term quality of life in critically ill patients with acute kidney injury treated with renal replacement therapy: a matched cohort study. Critical Care, 2015, 19, 289.	5.8	34
28	Burden of skin cancer in Belgium and cost-effectiveness of primary prevention by reducing ultraviolet exposure. Preventive Medicine, 2016, 93, 177-182.	3.4	34
29	Self-operated endovaginal telemonitoring versus traditional monitoring of ovarian stimulation in assisted reproduction: an RCT. Human Reproduction, 2014, 29, 1941-1948.	0.9	33
30	Resource use associated with type 2 diabetes in Africa, the Middle East, South Asia, Eurasia and Turkey: results from the International Diabetes Management Practice Study (IDMPS). BMJ Open Diabetes Research and Care, 2017, 5, e000297.	2.8	29
31	Cost-Effectiveness Evaluation of a Quadrivalent Human Papillomavirus Vaccine in Belgium. Pharmacoeconomics, 2009, 27, 231-245.	3.3	28
32	Real-world healthcare utilization in adult congenital heart disease: a systematic review of trends and ratios. Cardiology in the Young, 2019, 29, 553-563.	0.8	27
33	Health Economic Data Requirements and Availability in the European Union: Results of a Survey Among 10 European Countries. Value in Health Regional Issues, 2014, 4, 53-57.	1.2	26
34	Real-life practice study of the clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) in the management of actinic keratosis and basal cell carcinoma. European Journal of Dermatology, 2008, 18, 539-46.	0.6	26
35	Universal Mental Health Interventions for Children and Adolescents: A Systematic Review of Health Economic Evaluations. Applied Health Economics and Health Policy, 2020, 18, 155-175.	2.1	25
36	TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases. Orphanet Journal of Rare Diseases, 2020, 15, 127.	2.7	25

#	Article	IF	Citations
37	Self-reported health status in coronary heart disease patients: A comparison with the general population. European Journal of Cardiovascular Nursing, 2015, 14, 117-125.	0.9	24
38	Effectiveness of Pricing Strategies on French Fries and Fruit Purchases among University Students: Results from an On-Campus Restaurant Experiment. PLoS ONE, 2016, 11, e0165298.	2.5	24
39	Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease: Results from the EUROASPIRE IV survey. International Journal of Cardiology, 2018, 272, 20-25.	1.7	24
40	The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6-month analysis. BJU International, 2005, 96, 566-571.	2.5	23
41	Development of a prediction model for long-term quality of life in critically ill patients. Journal of Critical Care, 2018, 43, 133-138.	2.2	23
42	Delivering Diabetes Education through Nurse-Led Telecoaching. Cost-Effectiveness Analysis. PLoS ONE, 2016, 11, e0163997.	2.5	22
43	Economic Evaluation of Vaccines: Belgian Reflections on the Need for a Broader Perspective. Value in Health, 2021, 24, 105-111.	0.3	21
44	The combined impact of dependency on caregivers, disability, and coping strategy on quality of life after ischemic stroke. Health and Quality of Life Outcomes, 2019, 17, 31.	2.4	20
45	Effectiveness of an inâ€home respite care program to support informal dementia caregivers: A comparative study. International Journal of Geriatric Psychiatry, 2019, 34, 1534-1544.	2.7	19
46	Economic consequences of legal and illegal drugs: The case of social costs in Belgium. International Journal of Drug Policy, 2017, 44, 50-57.	3.3	18
47	Health economic evaluation of gene replacement therapies: methodological issues and recommendations. Journal of Market Access & Health Policy, 2020, 8, 1822666.	1.5	18
48	Costs of drugs for treatment of rheumatic diseases. RMD Open, 2016, 2, e000259.	3.8	17
49	Factors Associated with the Caregivers' Desire to Institutionalize Persons with Dementia: A Cross-Sectional Study. Dementia and Geriatric Cognitive Disorders, 2018, 46, 298-309.	1.5	16
50	A systematic review on costs and cost-effectiveness of screening and prevention of type 2 diabetes in women with prior gestational diabetes: Exploring uncharted territory. Diabetes Research and Clinical Practice, 2019, 147, 138-148.	2.8	16
51	Creating the BELgian COngenital heart disease database combining administrative and clinical data (BELCODAC): Rationale, design and methodology. International Journal of Cardiology, 2020, 316, 72-78.	1.7	16
52	Effectiveness and cost-effectiveness of an in-home respite care program in supporting informal caregivers of people with dementia: design of a comparative study. BMC Geriatrics, 2016, 16, 207.	2.7	15
53	Critically ill octogenarians and nonagenarians: evaluation of long-term outcomes, posthospital trajectories and quality of life one year and seven years after ICU discharge. Minerva Anestesiologica, 2017, 83, 598-609.	1.0	15
54	Strategies for newborn screening for cystic fibrosis: A systematic review of health economic evaluations. Journal of Cystic Fibrosis, 2018, 17, 306-315.	0.7	15

#	Article	IF	CITATIONS
55	Methodological Issues in Evaluating Cost Effectiveness of Adjuvant Aromatase Inhibitors in Early Breast Cancer. Pharmacoeconomics, 2008, 26, 409-423.	3.3	14
56	How to reform western care payment systems according to physicians, policy makers, healthcare executives and researchers: a discrete choice experiment. BMC Health Services Research, 2015, 15, 191.	2.2	13
57	Appropriateness of End-of-Life Care in People Dying From COPD. Applying Quality Indicators on Linked Administrative Databases. Journal of Pain and Symptom Management, 2018, 56, 541-550.e6.	1.2	13
58	Costâ€effectiveness of an inâ€home respite care program to support informal caregivers of persons with dementia: A modelâ€based analysis. International Journal of Geriatric Psychiatry, 2020, 35, 601-609.	2.7	13
59	The health-related social costs of alcohol in Belgium. BMC Public Health, 2017, 17, 958.	2.9	12
60	Osteopathic care for spinal complaints: A systematic literature review. PLoS ONE, 2018, 13, e0206284.	2.5	12
61	Resource Use During the Last SixÂMonths of Life Among COPD Patients: A Population-Level Study. Journal of Pain and Symptom Management, 2018, 56, 318-326.e7.	1.2	12
62	Do custom 3D-printed revision acetabular implants provide enough value to justify the additional costs? The health-economic comparison of a new porous 3D-printed hip implant for revision arthroplasty of Paprosky type 3B acetabular defects and its closest alternative. Orthopaedics and Traumatology: Surgery and Research, 2021, 107, 102600.	2.0	12
63	The potential health and economic effects of plant-based food patterns in Belgium and the United Kingdom. Nutrition, 2018, 48, 24-32.	2.4	11
64	The relationship between Home-time, quality of life and costs after ischemic stroke: the impact of the need for mobility aids, home and car modifications on Home-time. Disability and Rehabilitation, 2020, 42, 419-425.	1.8	11
65	Towards a comprehensive research design for studying integrated care. International Journal of Care Coordination, 2014, 17, 105-115.	0.4	10
66	Appropriateness of End-of-Life Care in People Dying With Dementia: Applying Quality Indicators on Linked Administrative Databases. Journal of the American Medical Directors Association, 2020, 21, 1093-1101.e1.	2.5	10
67	Methodological Considerations in Social Cost Studies of Addictive Substances: A Systematic Literature Review. Frontiers in Public Health, 2016, 4, 295.	2.7	9
68	PCSK9 inhibition, atherosclerotic cardiovascular disease, and health economics: Challenges at the crossroads. Journal of Clinical Lipidology, 2019, 13, 714-720.	1.5	9
69	The impact of professional and organizational identification on the relationship between hospital–physician exchange and customer-oriented behaviour of physicians. Human Resources for Health, 2015, 13, 8.	3.1	8
70	Variations in hospital costs after traffic injuries: The importance of sociodemographic aspects and comorbidities. Injury, 2017, 48, 2132-2139.	1.7	8
71	Resource Use During the Last 6 Months of Life of Individuals Dying with and of Alzheimer's Disease. Journal of the American Geriatrics Society, 2018, 66, 879-885.	2.6	8
72	Health and budget impact of combined HIV prevention – first results of the BELHIVPREV model. Acta Clinica Belgica, 2018, 73, 54-67.	1,2	8

#	Article	IF	CITATIONS
73	A model-based economic evaluation of four newborn screening strategies for cystic fibrosis in Flanders, Belgium. Acta Clinica Belgica, 2020, 75, 212-220.	1.2	8
74	Belgian multicentre study on lumbar spine imaging: Radiation dose and cost analysis; Evaluation of compliance with recommendations for efficient use of medical imaging. European Journal of Radiology, 2020, 125, 108864.	2.6	8
75	Valorising and Creating Access to Innovative Medicines in the European Union. Frontiers in Pharmacology, 2011, 2, 57.	3.5	7
76	Cost-effectiveness of prucalopride in the treatment of chronic constipation in the Netherlands. Frontiers in Pharmacology, 2015, 6, 67.	3.5	7
77	Direct Medical Costs of Pediatric Congenital Heart Disease Surgery in a Belgian University Hospital. World Journal for Pediatric & Discourge Heart Surgery, 2019, 10, 28-36.	0.8	7
78	A Trial-Based Cost-Utility Analysis of Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer. Cancers, 2020, 12, 132.	3.7	7
79	Provider accountability as a driving force towards physician–hospital integration: a systematic review. International Journal of Integrated Care, 2015, 15, e010.	0.2	7
80	Amortization of gene replacement therapies: A health policy analysis exploring a mechanism for mitigating budget impact of high-cost treatments. Health Policy, 2022, 126, 49-59.	3.0	7
81	Cost-effectiveness of retreatment with varenicline after failure with or relapse after initial treatment for smoking cessation. Preventive Medicine Reports, 2015, 2, 189-195.	1.8	6
82	How to govern physician–hospital exchanges: contractual and relational issues in Belgian hospitals. Journal of Health Services Research and Policy, 2014, 19, 145-152.	1.7	5
83	A proposal for value informed, affordable ("viaâ€) prices for innovative medicines. Journal of Medical Economics, 2019, 22, 1235-1239.	2.1	5
84	Methodology of the health economic evaluation of the Feel4Diabetes-study. BMC Endocrine Disorders, 2020, 20, 14.	2.2	5
85	Different levels of care for follow-up of adults with congenital heart disease: a cost analysis scrutinizing the impact on medical costs, hospitalizations, and emergency department visits. European Journal of Health Economics, 2021, 22, 951-960.	2.8	5
86	Facilitating More Efficient Negotiations for Innovative Therapies: A Value-Based Negotiation Framework. International Journal of Technology Assessment in Health Care, 2022, 38, e23.	0.5	5
87	Prehospital and in-hospital use of healthcare resources in patients surviving acute coronary syndromes: an analysis of the EPICOR registry. Open Heart, 2016, 3, e000347.	2.3	4
88	Association Between Clinical Pathways Leading to Medical Management and Prognosis in Patients With NSTEACS. Revista Espanola De Cardiologia (English Ed), 2017, 70, 817-824.	0.6	4
89	Opinions of general and adult congenital heart disease cardiologists on care for adults with congenital heart disease in Belgium: a qualitative study. Cardiology in the Young, 2019, 29, 1368-1374.	0.8	4
90	Intensifying dialysis: how far should we go and at what cost?. Nephrology Dialysis Transplantation, 2008, 24, 1077-1078.	0.7	3

#	Article	IF	Citations
91	The effectiveness and cost-effectiveness of an integrated osteoporosis care programme for postmenopausal women in Flanders: study protocol of a quasi-experimental controlled design. Archives of Osteoporosis, 2020, 15, 107.	2.4	3
92	Oral healthcare delivery in institutionalised older people: A healthâ€economic evaluation. Gerodontology, 2021, , .	2.0	3
93	Cost-effectiveness of exercise referral schemes: a systematic review of health economic studies. European Journal of Public Health, 2022, 32, 87-94.	0.3	3
94	The euros and sense of stents. Journal of Cardiovascular Medicine, 2011, 12, 878-882.	1.5	2
95	Further approaches to reduce the cost of renal replacement therapy. Nature Reviews Nephrology, 2017, 13, 720-720.	9.6	2
96	Costâ€"utility analysis of lifestyle interventions to prevent type 2 diabetes in women with prior gestational diabetes. European Journal of Public Health, 2020, 30, 396-401.	0.3	2
97	Cost-effectiveness analysis of a school- and community-based intervention to promote a healthy lifestyle and prevent type 2 diabetes in vulnerable families across Europe: the Feel4Diabetes-study. Preventive Medicine, 2021, 153, 106722.	3.4	2
98	A public health value-based healthcare paradigm for HIV. BMC Health Services Research, 2022, 22, 13.	2.2	2
99	Advances in health economic models and outcomes: a necessary condition to make advances in healthcare policy. Journal of Medical Economics, 2019, 22, 499-500.	2.1	1
100	Healthcare resource utilization in patients on lipid-lowering therapies outside Western Europe and North America: findings of the cross-sectional observational International ChoLesterol management Practice Study (ICLPS). Lipids in Health and Disease, 2020, 19, 64.	3.0	1
101	Influenza Vaccination in Patients With Congenital Heart Disease in the Pre-COVID-19 Era: Coverage Rate, Patient Characteristics, and Outcomes. Canadian Journal of Cardiology, 2021, 37, 1472-1479.	1.7	1
102	Health economic modelling of diabetic kidney disease in patients with type 2 diabetes treated with Canagliflozin in Belgium. Acta Clinica Belgica, 2021, , 1-10.	1.2	1
103	Achieving estimated health and budget gains through combined HIV prevention: theoretical results require real-world effort. Acta Clinica Belgica, 2018, 73, 167-167.	1.2	0
104	An early health technology assessment of 3D anatomic models in pediatric congenital heart surgery: potential cost-effectiveness and decision uncertainty. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 1107-1115.	1.4	0
105	Est-ce que les implants sur mesure par impression 3D ont une valeur suffisante pour justifier leur surcoût� Étude médico-économique comparant un implant poreux obtenu par impression 3D et son alternative proche pour le traitement des pertes de substances acétabulaires Paprosky 3B. Revue De Chirurgie Orthopedique Et Traumatologique. 2021. 107. 48-49.	0.0	0
106	Long-Term Outcome of Acute Coronary Syndromes in Patients on Chronic Oral Anticoagulants: Data from the EPICOR Study. Current Vascular Pharmacology, 2019, 18, 92-99.	1.7	0